A small study of 50 patients undergoing FOLFOX for CRC determined if adding aprepitant to standard antiemetic prophylactic treatment would improve CINV in this patient population.
A post-hoc analysis of 2 clinical trials was conducted to determine the safety and effectiveness of NEPA for managing CINV in patients with lung cancer who received platinum-based chemotherapy.
A randomized study was conducted to determine the efficacy of prophylactic prochlorperazine in reducing opioid-induced nausea and vomiting in patients with cancer receiving opioids for pain management.
Delayed CINV was improved significantly in patients receiving highly emetogenic chemotherapy for cancer when thalidomide was added to palonosetron and dexamethasone regimen.
Long-acting NK-1 receptor antagonist rolapitant demonstrates significant efficacy in managing CINV in patients receiving HEC or MEC for cancer.
Many patients can still experience UA-RINV despite prophylactic therapy; therefore, researchers explored the effectiveness and safety of dual prophylactic therapy with an NK1 receptor antagonist and a 5-HT3 receptor antagonist.
The Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO) have updated their recommendations for the prevention of nausea and vomiting following multiple-day chemotherapy.
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone significantly improved the prevention of CINV in patients with GI and CRC cancers receiving highly or moderately emetogenic chemotherapy.
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone improved quality of life.
Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.
[Cancer Management and Research] This review focuses on dronabinol and its role in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Loss of appetite and not eating are difficult aspects of cancer for patients' loved ones to understand. Continued and diligent nurse education can help both patients and families cope with this disturbing effect.
Personalized Antinausea Regimens More Effective in Cancer Patients Receiving Emetogenic ChemotherapyNovember 23, 2015
A personalized approach to treating nausea and vomiting, the most expected side effects of chemotherapy, is far more effective than the existing one-size-fits-all guidelines.
Ramosetron plus dexamethasone and aprepitant is as effective and tolerable as ondansetron.
Clinically relevant psychotropic side effects plus ineffectiveness halted study of cannabis use to prevent postoperative nausea.
Rolapitant demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting.
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomitingJuly 17, 2015
[Cancer Management and Research] This research examines the incidence of chemotherapy-induced nausea/vomiting (CINV) and treatment delay among patients receiving palonosetron versus other 5-hydroxytryptamine receptor antagonist (5-HT3 RA) antiemetics.
There is a perpetual gap between healthcare professionals and patient perceptions of incidence and impact on patients' daily life of CINV/RINV.
Granisetron transdermal system (GTS) may be appropriate for prevention of chemotherapy-induced nausea and vomiting (CINV) in lung cancer.
Is a comparison guide for common medications used for side-effect management, such as constipation, nausea, anxiety, etc. that includes a cost comparison available?
Akynzeo approved for the treatment chemotherapy-induced nausea and vomiting (CINV) in patients with cancer.
For patients receiving cisplatin-based chemotherapy, rolapitant can reduce nausea-related side effects.
Could a medication indicated for nausea and vomiting in pregnancy resolve the same symptoms in patients undergoing chemotherapy?
A ginger extract, 6-gingerol, improves chemotherapy-induced nausea and vomiting (CINV), according to findings from a phase 2 randomized trial presented at the 2014 Annual ASCO Meeting.
Patients who express pretreatment concern about treatment symptoms such as nausea and memory problems tend to suffer higher symptom burdens during and after anticancer treatment, suggests research.
What can nurses do to advocate for the use of medications such as lorezepam (Ativan) for anticipatory nausea when the physician is reluctant to prescribe antianxiety or sleep medications?
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
The 32-mg, single IV dose of the anti-nausea drug Zofran (ondansetron) will no longer be sold due to the potential for serious cardiac risks.
This fact sheet contains tips for patients dealing with nausea and loss of appetite resulting from cancer treatment.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
- Colorectal Cancer Screening Rate Increased by Digital Self-Ordering
- Presence of Iris Pigmented Lesions Indicates Melanoma Risk
- A Witness to Letting Go: Nursing Care at the End of Life
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|